Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019

por O’Horo, John, Challener, Douglas W., Anderson, Ryan J., Arndt, Richard F., Ausman, Sara E., Hall, Scott T., Heyliger, Alexander, Kennedy, Brian D., Sweeten, Perry W., Ganesh, Ravindra, Razonable, Raymund R.
Publicado 2022

A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19: The Mayo Clinic Model

por Razonable, Raymund R., Aloia, Nicole C.E., Anderson, Ryan J., Anil, Gokhan, Arndt, Lori L., Arndt, Richard F., Ausman, Sara E., Bell, Sarah J., Bierle, Dennis M., Billings, Marcie L., Bishop, Rachel K., Cramer, Carl H., Culbertson, Tracy L., Dababneh, Ala S., Derr, Amber N., Epps, Kevin, Flaker, Susan M., Ganesh, Ravindra, Gilmer, Mary A., Urena, Eric Gomez, Gulden, Christopher R., Haack, Tamara L., Hanson, Sara N., Herzog, Jenna R., Heyliger, Alexander, Hokanson, Lex D., Hopkins, Laura H., Horecki, Richard J., Krishna, Bipinchandra Hirisave, Huskins, W. Charles, Jackson, Tammy A., Johnson, Ryan R., Jorgenson, Betty, Kudrna, Cory, Kennedy, Brian D., Klingsporn, Mary K., Kottke, Brian, Larsen, Jennifer J., Lessard, Sarah R., Lutwick, Larry I., Malone, Edward J., Matoush, Jennifer A., Micallef, Ivana N., Moehnke, Darcie E., Mohamed, Muhanad, Ness, Colleena N., Olson, Shelly M., Orenstein, Robert, Palraj, Raj, Patel, Janki, Paulson, Damian J., Phelan, David, Peinovich, Margaret T., Ramsey, Wilford L., Rau-Kane, Taunya J., Reid, Kevin I., Reinschmidt, Karen J., Seville, Maria Teresa, Skold, Erin C., Smith, Jill M., Speicher, Leigh L., Spielman, Laurie A., Springer, Donna J., Sweeten, Perry W., Tempelis, Jennifer M., Tulledge-Scheitel, Sidna, Vergidis, Paschalis, Whipple, Daniel C., Wilker, Caroline G., Destro Borgen, Molly J.
Publicado 2021